GGrantIndex
← Leaderboards

Inotek Pharmaceuticals Corporation

Beverly, MA

Compare ↔
$36,309,073
Total funding
63
Grants

Funding over time

peak $2.7M · FY2005–07
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07

Funding mix

By agency

NIH$36,309,073 · 63

By mechanism

R44$23,235,221 · 16
R43$8,517,719 · 38
R01$4,055,461 · 5
R21$215,625 · 2
R29$205,545 · 1
R03$79,502 · 1

Investigators at Inotek Pharmaceuticals Corporation

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

1Andrew L Salzman$19,918,82821 gr2Csaba Szabo$15,133,75218 gr3Garry John Southan$7,950,26719 gr4Prakash Jagtap$6,029,47912 gr5Kanneganti Murthy$5,565,70113 gr6Fangming Zuo$1,288,3902 gr7Zsuzsanna Kinga Zsengeller$1,107,1554 gr8Ludmila Belayev$1,038,8501 gr

Largest grants

Novel therapy for female sexual dysfunction$1,463,183
R44 · FY2004 · HD
Inosine pro-drug: novel therapy for arthritis$1,396,706
R44 · FY2004 · AR
PARS inhibitor therapy for smoke inhalation$1,271,724
R44 · FY2003 · HL
A nitric oxide synthase inhibitor for uveitis$1,222,967
R44 · FY2005 · EY
ANTI-OXIDANT THERAPY OF SMOKE INHALATION INJURY$1,168,116
R44 · FY2000 · HL
Peroxynitrite decomposition catalyst for bowel disease$1,152,230
R44 · FY2002 · DK
Novel PARS inhibitor for therapy of colitis$1,092,059
R44 · FY2001 · DK
CBC-NO: SELECTIVE PULMONARY VASODILATOR FOR SEPSIS$1,006,442
R44 · FY2000 · GM
Catalytic antioxidant for hemorrhagic shock$978,243
R44 · FY2005 · GM
Novel antioxidants for periodontal disease$961,860
R44 · FY2003 · DE
Peroxynitrate neutralizing agents for stroke therapy$951,125
R44 · FY2003 · NS
Novel antioxidants for periodontal disease$916,102
R44 · FY2004 · DE
PARS INHIBITOR FOR THE THERAPY OF CIRCULATORY SHOCK$876,780
R44 · FY2001 · GM
A nitric oxide synthase inhibitor for uveitis$875,487
R44 · FY2007 · EY
Novel PARS inhibitor for therapy of colitis$857,140
R44 · FY2002 · DK
Ultrapotent PARS inhibitor for CNS trauma$791,155
R44 · FY2003 · NS
Adenosine-3 agonists for the suppression of arthritis$730,027
R44 · FY2002 · AR
Peroxynitrate neutralizing agents for stroke therapy$728,754
R44 · FY2002 · NS
Ultrapotent PARS inhibitor for CNS trauma$686,997
R44 · FY2002 · NS
PARS INHIBITOR FOR THE THERAPY OF CIRCULATORY SHOCK$668,501
R44 · FY2002 · GM